This pharmacoepidemiology study uses Medicare Part D data to describe changes in use of prescription drugs associated with an increase in fracture risk before and after fragility fractures.
This post hoc analysis of the Women’s Health Initiative study examines the effects of adherence to differing dietary recommendations and risk for hip fracture in postmenopausal women.
This randomized clinical trial compared the effects of 3 doses of monthly vitamin D on lower extremity function in community dwelling adults age 70 and older who had previously fallen.
This randomized clinical trial found that 1 dose of zoledronic acid improved bone mineral density over 2 years in frail elderly women with osteoporosis, but the clinical importance of nonsignificant increases in fracture and mortality needs further study.
This randomized clinical trial found that among men and women with elevated high-sensitivity C-reactive protein levels enrolled in a large trial of rosuvastatin therapy for cardiovascular disease, statin therapy did not reduce the risk of fracture.
Neuman et al describe patterns and predictors of mortality and functional decline in activities of daily living (ADLs) among nursing home residents after hip fracture. Ko and Morrison provide an Invited Commentary.
Bauer et al test methods of predicting fracture risk among women who have discontinued alendronate therapy after 4 to 5 years of treatment.
McCullough and colleagues compare major medical outcomes following treatment of osteoporotic
vertebral fractures with spinal augmentation or conservative therapy.